0000899243-21-043678.txt : 20211109 0000899243-21-043678.hdr.sgml : 20211109 20211109192509 ACCESSION NUMBER: 0000899243-21-043678 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20211105 FILED AS OF DATE: 20211109 DATE AS OF CHANGE: 20211109 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kuriakose Emil CENTRAL INDEX KEY: 0001892413 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36644 FILM NUMBER: 211393793 MAIL ADDRESS: STREET 1: 30 PLAYER POINT DRIVE CITY: THE WOODLANDS STATE: TX ZIP: 77382 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Calithera Biosciences, Inc. CENTRAL INDEX KEY: 0001496671 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 272366329 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 343 OYSTER POINT BLVD #200 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-870-1000 MAIL ADDRESS: STREET 1: 343 OYSTER POINT BLVD #200 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2021-11-05 0 0001496671 Calithera Biosciences, Inc. CALA 0001892413 Kuriakose Emil C/O CALITHERA BIOSCIENCES, INC. 343 OYSTER POINT BLVD. #200 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 CHIEF MEDICAL OFFICER Common Stock 60467 D STOCK OPTION (RIGHT TO BUY) 15.75 2027-09-28 COMMON STOCK 38000 D STOCK OPTION (RIGHT TO BUY) 5.61 2028-10-08 COMMON STOCK 12667 D STOCK OPTION (RIGHT TO BUY) 4.64 2029-01-09 COMMON STOCK 21000 D STOCK OPTION (RIGHT TO BUY) 7.41 2030-01-16 COMMON STOCK 40000 D STOCK OPTION (RIGHT TO BUY) 2.98 2031-01-19 COMMON STOCK 33375 D Includes 14,089 shares acquired at various dates pursuant to the Company's 2014 Employee Stock Purchase Plan. Includes 26,961 shares acquired upon the vesting of a restricted stock unit award, net of shares sold to satisfy tax obligations, arising out of the vesting of previously granted restricted stock units. Includes an aggregate of 19,417 shares of common stock to be acquired upon the vesting of Restricted Stock Unit awards granted to the Reporting Person. The Restricted Stock Units shall vest as follows: a) 7,417 restricted stock units shall vest according to the following schedule: one-fourth (1/4th) of the shares subject to the Restricted Stock Unit award will vest each year after January 20, 2021 until the Restricted Stock Units are fully vested, b) 12,000 restricted stock units shall fully vest on January 3, 2022. The Restricted Stock Units shall be subject to accelerated vesting as set forth in the Reporting Person's employment agreement with the Company. One-fourth (1/4th) of the Option vests one year after September 29, 2017; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the Reporting Person's employment agreement with the Company. One-fourth (1/4th) of the Option vests one year after October 9, 2018; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the Reporting Person's employment agreement with the Company. One-fourth (1/4th) of the Option vests one year after January 10, 2019; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the Reporting Person's employment agreement with the Company. One-fourth (1/4th) of the Option vests one year after January 17, 2020; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the Reporting Person's employment agreement with the Company. One-fourth (1/4th) of the Option vests one year after January 20, 2021; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the Reporting Person's employment agreement with the Company. /s/ Emil Kuriakose, Name: Emil Kuriakose 2021-11-09 EX-24 2 attachment1.htm EX-24 DOCUMENT

                               POWER OF ATTORNEY

       Know all by these presents, that the undersigned hereby constitutes and
appoints each of Susan Molineaux, Stephanie Wong, Sumita Ray, John McKenna and
Seth Gottlieb, signing individually, the undersigned's true and lawful attorneys
-in fact and agents to:

            (1) execute for and on behalf of the undersigned, in the
undersigned's capacity as an officer, director or beneficial owner of more than
10% of aregistered class of securities of Calithera Biosciences, Inc. (the
"Company"),Forms 3, 4 and 5 (including any amendments thereto) in accordance
with Section 16(a) of the Securities Exchange Act of 1934, as amended (the
"Exchange Act")and the rules thereunder and a Form ID, Uniform Application for
 Access Codes toFile on EDGAR;

            (2) do and perform any and all acts for and on behalf of the
undersigned that may be necessary or desirable to execute such Forms 3, 4 or 5
or Form ID (including any amendments thereto) and timely file such forms with
the United States Securities and Exchange Commission and any stock exchange or
similarauthority; and

            (3) take any other action of any nature whatsoever in connection
with theforegoing which, in the opinion of such attorney-in-fact, may be of
benefit, in the best interest of, or legally required by, the undersigned, it
being understood that the documents executed by such attorney-in-fact on behalf
of the undersigned pursuant to this Power of Attorney shall be in such form and
shall contain such terms and conditions as such attorney-in-fact may approve in
such attorney-in-fact's discretion.

       The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted. The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Exchange Act.

       This Power of Attorney shall remain in full force and effect until the
earliest to occur of (a) the undersigned is no longer required to file Forms 3,
4 and 5 with respect to the undersigned's holdings of and transactions in
securities issued by the Company, (b) revocation by the undersigned in a signed
writing delivered to the foregoing attorneys-in-fact or (c) as to any attorney-
in-fact individually, until such attorney-in-fact is no longer employed by the
Company or Cooley LLP.

       IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of November 5, 2021.

                                       /s/ Emil Kuriakose
                                       ------------------------------------
                                       EMIL KURIAKOSE